Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference

Courtney M. Kloske*, Michael E. Belloy, Elizabeth E. Blue, Gregory R. Bowman, Maria C. Carrillo, Xiaoying Chen, Ornit Chiba-Falek, Albert A. Davis, Gilbert Di Paolo, Francesca Garretti, David Gate, Lesley R. Golden, Jay W. Heinecke, Joachim Herz, Yadong Huang, Costantino Iadecola, Lance A. Johnson, Takahisa Kanekiyo, Celeste M. Karch, Anastasia KhvorovaSascha J. Koppes-den Hertog, Bruce T. Lamb, Paige E. Lawler, Yann Le Guen, Alexandra Litvinchuk, Chia Chen Liu, Simin Mahinrad, Edoardo Marcora, Claudia Marino, Danny M. Michaelson, Justin J. Miller, Josh M. Morganti, Priyanka S. Narayan, Michel S. Naslavsky, Marlies Oosthoek, Kapil V. Ramachandran, Abhirami Ramakrishnan, Ana Caroline Raulin, Aiko Robert, Rasha N.M. Saleh, Claire Sexton, Nilomi Shah, Francis Shue, Isabel J. Sible, Andrea Soranno, Michael R. Strickland, Julia Tcw, Manon Thierry, Li Huei Tsai, Ryan A. Tuckey, Jason D. Ulrich, Rik van der Kant, Na Wang, Cheryl L. Wellington, Stacie C. Weninger, Hussein N. Yassine, Na Zhao, Guojun Bu, Alison M. Goate, David M. Holtzman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

INTRODUCTION: The apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer's disease (AD), with distinct apoE isoforms exerting diverse effects. apoE influences not only amyloid-beta and tau pathologies but also lipid and energy metabolism, neuroinflammation, cerebral vascular health, and sex-dependent disease manifestations. Furthermore, ancestral background may significantly impact the link between APOE and AD, underscoring the need for more inclusive research. METHODS: In 2023, the Alzheimer's Association convened multidisciplinary researchers at the “AAIC Advancements: APOE” conference to discuss various topics, including apoE isoforms and their roles in AD pathogenesis, progress in apoE-targeted therapeutic strategies, updates on disease models and interventions that modulate apoE expression and function. RESULTS: This manuscript presents highlights from the conference and provides an overview of opportunities for further research in the field. DISCUSSION: Understanding apoE's multifaceted roles in AD pathogenesis will help develop targeted interventions for AD and advance the field of AD precision medicine. Highlights: APOE is a central player in the pathogenesis of Alzheimer's disease. APOE exerts a numerous effects throughout the brain on amyloid-beta, tau, and other pathways. The AAIC Advancements: APOE conference encouraged discussions and collaborations on understanding the role of APOE.

Original languageEnglish
JournalAlzheimer's and Dementia
DOIs
StateAccepted/In press - 2024

Funding

FundersFunder number
Massachusetts General Hospital Executive Committee
BrightFocus foundation postdoctoral fellowship A2021015F
Medical Research Council
“Training in Translational Research in Alzheimer's and Related Dementias (TRIAD
Edward N. and Della L. Thome Memorial Foundation
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
JPB Foundation
European Union's Horizon 2020 research and innovation program
NIH‐NIDDK
Remondi Family Foundation
Alzheimer's Drug Discovery FoundationR01 AG081228, T32 GM008361, R01 AG068395, 1U19AG069701
Alzheimer's Drug Discovery Foundation
NIAR41 AG077992, F32AG08483, R01AG061186, T32 AG078110, R01HL149685, 23AARG‐1026607, R01 AG057522
NIH NIAR01AG062837, T32AG058518
Cure Alzheimer's FundRF1AG078362, R01AG66395, U01AG058635, R21AG056518, R01AG067063, RF1AG076124, GC‐201711‐2014197, P30AG066530, R01AG055770, RF1AG046205, R01AG054434, U54NS110435
Cure Alzheimer's Fund
NIH‐NIAU19 AG069701
U.S. Department of DefenseW81XWH‐21‐1‐0093
U.S. Department of Defense
National Institute of Neurological Disorders and StrokeUH3 NS100121, RF1 NS110048
National Institute of Neurological Disorders and Stroke
Alzheimer's AssociationAARF‐20‐683984
Alzheimer's Association
BrightFocus FoundationP01AG073082, R01AG062550, R56AG081417 NIH U19AG069701, R01AG081421, A2022010F, NS126467 ApoE4, R01AG080589, R01AG060056
BrightFocus Foundation
National Institute on AgingRF1AG077627, R01 AG054671, R01AG059737, U19AG069701, U01AG058589, RF1AG067194
National Institute on Aging
NuBrain ConsortiumMR/T001852/1
Alzheimer's DiseaseU54 AG065181, U54AG054345, GM131839‐03, RF1 AG074566
National Institutes of HealthDP5 OD019833
National Institutes of Health
National Institute of General Medical SciencesP20GM148326
National Institute of General Medical Sciences
ECOR3RF1NS118558, P30EY003790, 5R01AG070830, T32AG05851804
CNPq7DP5OD028133, 304746/2022‐3
NSFR01AG082362, P30AG066512, R01AG083941, K01AG062683, R56AG078733, P01AG060882.R, DGE‐1745038
H2020 Marie Skłodowska-Curie Actions890650
H2020 Marie Skłodowska-Curie Actions

    Keywords

    • APOE
    • Alzheimer's disease
    • apolipoprotein E
    • conference proceedings
    • dementia
    • lipids
    • microglia
    • neuroinflammation
    • risk factor
    • therapeutics
    • vasculature

    Fingerprint

    Dive into the research topics of 'Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference'. Together they form a unique fingerprint.

    Cite this